Semaglutide explained: the science, the evidence, and what it means for you

How the STEP 1 trial reshaped the conversation around weight loss medicine

Weight management research rarely produces results that make news outside specialist journals. Semaglutide was different. The STEP 1 trial enrolled 1,961 adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition, and ran for 68 weeks. Those taking semaglutide 2.4mg lost an average of around 15% of their starting body weight, roughly three times what had been seen with older medicines in the same field. Placebo participants lost around 2.4%.

These were not cherry-picked results. Participants came from 16 countries, and the findings held across subgroups. The NHS medicines page for semaglutide reflects this evidence base and outlines what the medicine is, how it is taken, and what to watch for. The consistency of the data was a key reason NICE subsequently recommended it for NHS use.

What the trial also showed was that most of the weight returned when participants stopped taking the medicine, which is why continued treatment and lifestyle support matter. Semaglutide is not a short course; it is a long-term intervention, and that shapes how clinicians discuss it with patients. For a broader look at how semaglutide fits within the full range of licensed weight-loss options, the weight-loss treatment overview on this site sets out the landscape clearly.

What semaglutide actually does in the body, and why the dose ladder exists

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. It signals fullness to the brain, slows gastric emptying so food stays with you longer, and moderates the drive to eat between meals. Semaglutide binds to GLP-1 receptors with high affinity and has a much longer half-life than the natural hormone, which is why a single weekly injection (or a daily tablet) is enough to maintain a meaningful effect.

The dose schedule exists for a practical reason: starting at a low dose and stepping up every four weeks gives the body time to adjust, which significantly reduces early gastrointestinal side effects. Nausea is the most commonly reported symptom, especially in the first few weeks, and it tends to settle as the body acclimatises. Diarrhoea, constipation, indigestion and tiredness are also reported, particularly around dose changes.

The Wegovy treatment page covers the licensed injection schedule in detail. For those interested in the oral route approved in June 2026, the escalation runs from 1.5mg, where treatment typically begins and the body starts to adjust to the medicine, through 4mg, the next step up as tolerance builds, and 9mg, before reaching the 25mg maintenance dose, taken first thing in the morning on an empty stomach with a small amount of water, at least 30 minutes before food or other medicines, a routine some people find easier to build into their day than a weekly injection. No refrigeration is needed for the tablets, which makes travel straightforward.

Licensed uses, the Ozempic distinction, and what NICE actually says

Semaglutide sits behind two separate brand names in the UK, and the distinction matters. Wegovy (in both injection and tablet form) is licensed for weight management. Ozempic (the same molecule at lower doses) is licensed for type 2 diabetes. They are not the same product and are not prescribed interchangeably. If you have read about semaglutide in the context of diabetes management, that is Ozempic; this page is about the weight-management licence.

NICE recommended semaglutide for weight management in March 2023 (TA875), but with specific conditions attached. On the NHS it is available only through specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity, with thresholds 2.5 kg/m² lower for some ethnic backgrounds. That is a meaningful restriction. Many people who would benefit clinically do not meet the NHS criteria, or face waiting lists that run to months or years.

Private prescription routes offer a regulated alternative. Understanding how Wegovy is priced in the UK can help set expectations before a consultation, since costs vary by dose and provider. The key point is that any legitimate private route still requires a proper clinical assessment, a prescriber reviews your medical history, weight, and health before issuing a prescription. That assessment is not a formality; it is the safety mechanism the medicine's prescription-only status exists to protect.

Verifying a provider and what receiving treatment actually looks like

Because semaglutide has attracted significant public interest, it has also attracted unregulated sellers. The MHRA has warned repeatedly about fake weight-loss pens sold through social media and unofficial websites, some counterfeit pens have contained insulin, with serious consequences for people who bought them thinking they were getting a licensed medicine. The test of a legitimate provider is straightforward: look them up on the GPhC pharmacy register. Every registered online pharmacy in the UK has a premises number you can verify in seconds. If a seller cannot be found there, do not order from them.

At a regulated pharmacy, the process looks quite different from a social-media purchase. A prescriber reviews your consultation (not software) and if treatment is clinically appropriate, your pen arrives via a tracked courier in plain, unbranded packaging. You will get a DPD notification on your phone before it arrives, and the pen itself is a pre-filled device with no assembly required. That combination of clinical oversight and reliable logistics is what legitimate supply actually involves.

If you want to understand whether semaglutide might be suitable for your situation, our clinical team carries out same-day prescription reviews for eligible patients. You can also read more about semaglutide as a treatment or explore common questions about the consultation process before you start. When you are ready, check your eligibility, the consultation is free, and there is no obligation.